Mumbai (Maharashtra) [India], November 3 (ANI): Kareena Kapoor Khan couldn't contain her excitement after India's women's cricket team scripted history by lifting their maiden ICC Women's World Cup ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Kala Pharmaceuticals ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Arlington biotech has been ...

Kala Bio said it laid off most of its employees after receiving notice that its lender, Oxford Finance, intends to foreclose on all of its remaining assets. The move follows the biotech company's ...

In Punjab, more than 40 people died, nearly 2,000 villages were submerged, over 350,000 people were affected, and 1.75 lakh hectares of crops were destroyed. Rebuilding Punjab, however, will be a long ...

Lucknow: The Khadi Bhawan in Lucknow came alive on Friday with the inauguration of the Mati Kala Mahotsav 2025, a 10-day celebration of Uttar Pradesh's traditional pottery and terracotta craftsmanship ...

Amid the Bihar Elections 2025, the ongoing dispute between Bhojpuri actor Pawan Singh and his wife Jyoti Singh has made headlines again. This time Jyoti Singh has retorted to her husband's allegations ...

Jyoti Singh, wife of Bhojpuri singer-actor and BJP leader Pawan Singh, was seen crying and pleading outside his Lucknow residence. The video, now widely shared online, shows Jyoti confronting police ...

Kala Bio, Inc. (NASDAQ:KALA), a biotech company with a market capitalization of $10.74 million and showing significant stock volatility, announced it received a written notice of default from Oxford ...

Shares of Kala Bio plummeted Monday after the company said a study of its treatment for Persistent Corneal Epithelial Defect, an eye defect, missed its primary endpoints and it would stop development ...

Kala Bio will stop developing its experimental treatment for a type of eye condition after it failed to meet the main goal in a mid-stage study, sending the drug developer's shares down 93% in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Arlington biotech's stock ...